49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
9 citations,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
17 citations,
March 2018 in “Pediatric dermatology” Hydroxychloroquine may help treat alopecia areata in children.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
24 citations,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
1 citations,
November 2017 in “Dermatologic therapy” JAK inhibitors show promise as a future treatment for hair loss.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
34 citations,
October 2017 in “Archivos Argentinos De Pediatria” Alopecia Areata is a complex, unpredictable autoimmune hair loss condition with limited treatment options and a significant psychological impact.
37 citations,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
44 citations,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
22 citations,
September 2017 in “Skin appendage disorders” Ruxolitinib helped a man regrow his beard after years of hair loss.
16 citations,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
30 citations,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
83 citations,
June 2017 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help children with alopecia areata regrow hair.
8 citations,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
78 citations,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
25 citations,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
49 citations,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
13 citations,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
16 citations,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
1 citations,
November 2016 in “Journal of dermatological treatment” Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
26 citations,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
95 citations,
July 2016 in “Journal of The American Academy of Dermatology” People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
24 citations,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
70 citations,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
39 citations,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
82 citations,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
157 citations,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
96 citations,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
41 citations,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
17 citations,
August 2015 in “Expert Opinion on Pharmacotherapy” The document concludes that oral finasteride and topical minoxidil are effective for genetic hair loss, while other treatments for different types of hair loss show promise but need more research.
144 citations,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
184 citations,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
162 citations,
October 2014 in “Autoimmunity reviews” Alopecia areata is caused by the immune system attacking hair follicles.
52 citations,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
701 citations,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
421 citations,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
109 citations,
May 2011 in “Dermatologic Therapy” Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.
